Although effective in the treatment of immunodysregulatory diseases such as psoriasis, targeted immunosuppressive agents may confer risks of both enhanced susceptibility to infection and decreased responsiveness to vaccination. In a recent study, Krueger et al. (this issue) investigated these issues by testing the immune response to both a model antigen and a therapeutic vaccination in psoriasis patients during and after treatment with an LFA-1 inhibitor, efalizumab.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/jid.2008.291 | DOI Listing |
Publication Analysis
Top Keywords
balancing immunity
4
immunity immunosuppression
4
immunosuppression vaccinating
4
vaccinating patients
4
patients receiving
4
receiving treatment
4
treatment efalizumab
4
efalizumab effective
4
effective treatment
4
treatment immunodysregulatory
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!